1. Home
  2. FOR vs GHRS Comparison

FOR vs GHRS Comparison

Compare FOR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forestar Group Inc

FOR

Forestar Group Inc

HOLD

Current Price

$30.31

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo GH Research PLC

GHRS

GH Research PLC

HOLD

Current Price

$14.70

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOR
GHRS
Founded
2005
2018
Country
United States
Ireland
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
FOR
GHRS
Price
$30.31
$14.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
10
Target Price
$31.75
$32.90
AVG Volume (30 Days)
197.6K
223.0K
Earning Date
01-20-2026
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.27
N/A
Revenue
$1,685,000,000.00
N/A
Revenue This Year
$0.52
N/A
Revenue Next Year
$7.72
N/A
P/E Ratio
$9.27
N/A
Revenue Growth
15.89
N/A
52 Week Low
$18.00
$7.98
52 Week High
$30.74
$19.51

Technical Indicators

Market Signals
Indicator
FOR
GHRS
Relative Strength Index (RSI) 71.28 45.48
Support Level $29.13 $14.50
Resistance Level $29.87 $15.88
Average True Range (ATR) 0.95 0.89
MACD 0.32 -0.19
Stochastic Oscillator 93.22 35.60

Price Performance

Historical Comparison
FOR
GHRS

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: